Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at the Hospital Clinic of Barcelona Clinical Trials Unit were prospectively r...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, Schettini, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198872/
https://www.ncbi.nlm.nih.gov/pubmed/36625938
http://dx.doi.org/10.1007/s00262-022-03360-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198872/
https://www.ncbi.nlm.nih.gov/pubmed/36625938
http://dx.doi.org/10.1007/s00262-022-03360-9

Ejemplares similares